Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis' Biologics PipelineBusiness Wire • 11/03/22
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPαBusiness Wire • 11/01/22
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of ExatecanBusiness Wire • 11/01/22
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 11/01/22
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022Business Wire • 10/26/22
Wall Street Analysts Predict a 74% Upside in Exelixis (EXEL): Here's What You Should KnowZacks Investment Research • 10/25/22
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a SolutionThe Motley Fool • 10/19/22
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022Business Wire • 10/18/22
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 TrialBusiness Wire • 10/04/22
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022Business Wire • 09/10/22
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022Business Wire • 09/07/22
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in SeptemberBusiness Wire • 09/06/22